Vascular Medicine Conference-CVC 2026

Hypercoagulable states refer to conditions where the blood demonstrates an abnormal propensity to clot, increasing the risk for events such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These conditions can be inherited—such as Factor V Leiden mutation or prothrombin gene mutation—or acquired, as seen in scenarios like antiphospholipid syndrome, malignancy, or extended periods of immobility.

Notably, individuals may remain asymptomatic until a thrombotic event occurs, which underscores the importance of early identification in those at elevated risk. Management strategies typically center on minimizing clot formation through lifestyle modifications, use of anticoagulant medications, and vigilant monitoring during higher-risk situations (e.g., surgery or pregnancy). Determining the underlying etiology is crucial, as it shapes both the duration and intensity of therapy required to reduce the risk of recurrence. With appropriate intervention, the likelihood of severe complications can be substantially diminished, thereby improving outcomes for individuals with hypercoagulable states.